Man­u­fac­tur­ing roundup: As­traZeneca and Sam­sung ink $350M deal; Michi­gan CD­MO com­pletes ex­pan­sion

Sam­sung’s biotech arm and As­traZeneca are look­ing to work to­geth­er on a con­tract man­u­fac­tur­ing agree­ment.

Ac­cord­ing to a re­port from Ko­rea’s Yon­hap News Agency, Sam­sung Bi­o­log­ics has signed a let­ter of in­tent with As­traZeneca on a co­op­er­a­tion deal val­ued at an es­ti­mat­ed $350 mil­lion, but no oth­er de­tails on the deal were avail­able.

Sam­sung Bi­o­log­ics told Yon­hap that the com­pa­nies ex­changed a sep­a­rate let­ter of in­tent last year to col­lab­o­rate on bio­phar­ma­ceu­ti­cal man­u­fac­tur­ing, but now the col­lab­o­ra­tion has grown due to in­creased de­mand from As­traZeneca.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER